The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2021 | Customizing CLL care with BTK Inhibitors
Jacqueline Barrientos, MD, MS, Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, provides an overview of Bruton’s tyrosine kinase (BTK) inhibitors in treating patients with chronic lymphocytic leukemia (CLL). BTK inhibitors such as ibrutinib, acalabrutinib, and zanubrutinib have improved survival outcomes in patients with mutations including 17p and 11q deletions. In the Phase III ELEVATE CLL R/R trial (NCT02477696) investigating acalabrutinib against ibrutinib in patients with CLL, both BTK inhibitors resulted in similar outcomes, but acalabrutinib was associated with fewer side effects including atrial fibrillation. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
